This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
TRUST THE EYLEA EXPERIENCE
EYLEA 2 mg is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).
The tried-and-trusted EYLEA molecule is supported by extensive evidence in both pivotal trials and clinical practice.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Abbreviations
DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. MoA, mechanism of action. nAMD, neovascular age-related macular degeneration. R&D, research and development. RVO, retinal vein occlusion. VEGF, vascular endothelial growth factor.
PP-EYL-GB-2793 | March 2025
- Referencesexpand_less
- 1EYLEA® 40 mg/mL Summary of Product Characteristics.
- 2Bayer. Data on File. EYLO020.
- 3Papadopoulos N, et al. Angiogenesis 2012;15:171–185.
- 4Kanda A, et al. Sci Rep 2015;5:17946.
- 5Amadio M, et al. Pharmacol Res 2016;103:253–269.
- 6EMA. EYLEA EPAR assessment report 2012. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/eylea. Accessed: August 2024.
- 7Fauser S & Muether PS. Br J Ophthalmol 2016;100:1494–1498.